The for-profit operator of healthcare facilities scaled back financial guidance for the year following payer mix shifts due to health insurance exchanges.
HCA Healthcare on Tuesday reported preliminary second-quarter revenue above Wall Street expectations.
Investors need to pay close attention to HCA stock based on the movements in the options market lately.
HCA Healthcare remains a soft 'buy' despite recent underperformance, with fundamentals improving and shares attractively priced on an absolute basis. HCA's revenue and profitability continue to grow, driven by Medicare/Medicaid, increased equivalent admissions, and higher revenue per admission, even as the physical footprint shrinks. Management sustains shareholder returns through dividends and aggressive buybacks, with a 6.9% reduction in share count and $9.18 billion in remaining buyback capacity.
HCA is expanding hospitals, ERs and outpatient sites while investing billions in new capacity to support future healthcare demand and long-term growth.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
HCA Healthcare highlights promising pediatric CRISPR gene therapy results as expanding specialty care and research investments support its long-term growth strategy.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
HCA plans to acquire CHCP, expanding healthcare education efforts and boosting its pipeline of trained professionals across hospitals and care sites.
HCA Healthcare, Inc. (HCA) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript